When demand is slack and market is competitive, firms follow which of the following pricing methods?

When demand is slack and market is competitive, firms follow which of the following pricing methods? Correct Answer Marginal cost pricing

The correct answer is Marginal cost pricing

Key PointsMarginal Cost Pricing:

  • Marginal-cost pricing is the practise of adjusting a product's price to equal the additional cost of producing an extra unit of production.
  • According to this strategy, a manufacturer only charges the addition to total cost arising from materials and direct labour for each product unit sold.
  • During periods of low sales, businesses frequently set prices close to marginal cost.

Important Points

  •  Marginal Cost Price is a pricing strategy that requires businesses to determine prices for goods and services at a rate higher than the marginal cost of production, or MCP.
  • This is a relatively simple statistic that can be used to represent the cost of producing an additional unit of a given output of any type of setting using this special pricing tool.
  • It is common for the approach to play a role in setting prices for utilities and other situations in which competition for consumers follows the pricing method.

Related Questions

In pricing one new emerging model is Outcome Based Pricing Model. When pricing is done for the IT industry., which of these will represent Outcome Based Pricing?
In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.